GB0127673D0 - Polypeptide - Google Patents

Polypeptide

Info

Publication number
GB0127673D0
GB0127673D0 GBGB0127673.2A GB0127673A GB0127673D0 GB 0127673 D0 GB0127673 D0 GB 0127673D0 GB 0127673 A GB0127673 A GB 0127673A GB 0127673 D0 GB0127673 D0 GB 0127673D0
Authority
GB
United Kingdom
Prior art keywords
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB0127673.2A
Other versions
GB2370572B (en
GB2370572A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9825303.2A external-priority patent/GB9825303D0/en
Priority claimed from GBGB9901739.4A external-priority patent/GB9901739D0/en
Priority claimed from GBGB9917995.4A external-priority patent/GB9917995D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority claimed from GB0014986A external-priority patent/GB2347932B/en
Publication of GB0127673D0 publication Critical patent/GB0127673D0/en
Publication of GB2370572A publication Critical patent/GB2370572A/en
Application granted granted Critical
Publication of GB2370572B publication Critical patent/GB2370572B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
GB0127673A 1998-11-18 1999-11-18 Use of a professional antigen presenting cell Expired - Fee Related GB2370572B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9825303.2A GB9825303D0 (en) 1998-11-18 1998-11-18 Vector
GBGB9901739.4A GB9901739D0 (en) 1999-01-27 1999-01-27 Polypeptide
GBGB9917995.4A GB9917995D0 (en) 1999-07-30 1999-07-30 Polypeptide
GB0014986A GB2347932B (en) 1998-11-18 1999-11-18 Vectors for the delivery of 5T4 antigen

Publications (3)

Publication Number Publication Date
GB0127673D0 true GB0127673D0 (en) 2002-01-09
GB2370572A GB2370572A (en) 2002-07-03
GB2370572B GB2370572B (en) 2003-05-07

Family

ID=27447855

Family Applications (3)

Application Number Title Priority Date Filing Date
GB0127673A Expired - Fee Related GB2370572B (en) 1998-11-18 1999-11-18 Use of a professional antigen presenting cell
GB0127675A Withdrawn GB2370573A (en) 1998-11-18 1999-11-18 Poxviral vectors
GB0127669A Expired - Fee Related GB2370571B (en) 1998-11-18 1999-11-18 A modified 5t4 antigen

Family Applications After (2)

Application Number Title Priority Date Filing Date
GB0127675A Withdrawn GB2370573A (en) 1998-11-18 1999-11-18 Poxviral vectors
GB0127669A Expired - Fee Related GB2370571B (en) 1998-11-18 1999-11-18 A modified 5t4 antigen

Country Status (1)

Country Link
GB (3) GB2370572B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
SI1335987T2 (en) 2000-11-23 2016-10-28 Bavarian Nordic A/S Modified vaccinia ankara virus variant
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
PT1420822E (en) 2002-04-19 2007-09-04 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
DE60320520T3 (en) 2002-09-05 2019-05-09 Bavarian Nordic A/S METHOD FOR THE AMPLIFICATION OF A POXVIRUS IN SERUM-FREE CONDITIONS
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AU3353989A (en) * 1988-03-04 1989-09-22 Cancer Research Campaign Technology Limited Improvements relating to antigens
AU6504596A (en) * 1995-07-21 1997-02-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity

Also Published As

Publication number Publication date
GB2370571B (en) 2003-05-07
GB2370571A (en) 2002-07-03
GB0127675D0 (en) 2002-01-09
GB0127669D0 (en) 2002-01-09
GB2370573A (en) 2002-07-03
GB2370572B (en) 2003-05-07
GB2370572A (en) 2002-07-03

Similar Documents

Publication Publication Date Title
PL344341A1 (en) Peptides
DE59912562D1 (en) Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung
EP1142992A4 (en) Polypeptides
HK1039158A1 (en) Nlk1-interacting proteins
GB0127675D0 (en) Polypeptide
GB9825854D0 (en) Peptide
EP1103604A4 (en) Novel polypeptide
GB9815505D0 (en) Polypeptide derivatives
EP1197556A4 (en) Useful polypeptide
IL139873A0 (en) Angoistatin-binding protein
GB9812675D0 (en) Peptides
GB9828704D0 (en) Proteins
GB9816337D0 (en) Proteins
GB9828880D0 (en) Protein
GB9807890D0 (en) Peptides
GB0224538D0 (en) Polypeptide
HK1045173A1 (en) Polypeptide
GB9819387D0 (en) Polypeptide
GB9812607D0 (en) Protein
GB9809566D0 (en) Protein
GB9819038D0 (en) Protein
EP1127066A4 (en) Modified proteins
GB9816335D0 (en) Proteins
GB0320970D0 (en) Proteins
GB9816336D0 (en) Proteins

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20171118